FIELD: medicine.
SUBSTANCE: to assess the type of muscle fibers, histological sections for determination of oxidative, oxidation-glycolytic and glycolytic types of muscle fibers are successively placed first in a 1% CaCI2 solution, then in a 2% CoCI2 solution and further in a 1% ammonium sulfide solution, they are subsequently placed in an acidic medium where the "fast" myosin of glycolytic fibers is inactivated and into an alkaline medium for determination of the oxidation-glycolytic and glycolytic types where the "slow" myosin of oxidative fibers is inactivated. Oxidizing fibers are coloured black on the cut, reddish-glycolytic fibers are gray, and glycolytic fibers are white, the type of muscle fibers is determined by their cross-sectional area, and enzymes are used as markers: succinate dehydrogenase - to evaluate the activity of oxidative processes in mitochondria and lactate dehydrogenase - to determine the intensity of glycolysis in the cell cytoplasm.
EFFECT: method allows to reliably determine the type of muscle fiber when it is available.
3 tbl, 5 dwg
Title | Year | Author | Number |
---|---|---|---|
METHOD OF INCREASING STABILITY TO HUMAN MUSCLES' TIREDNESS AND KEEPING OF MAXIMAL RANDOM POWER | 2005 |
|
RU2306960C2 |
METHOD FOR DETERMINATION OF GENETIC BASE OF COMMON TYPES OF HIGHER NERVOUS ACTIVITY | 2008 |
|
RU2386399C9 |
METHOD TO PREVENT DEVELOPMENT OF SKELETAL MUSCLE FATIGUE | 2023 |
|
RU2814077C1 |
METHOD FOR DETERMINING THE ENERGY METABOLISM ENZYME DYSFUNCTION IN RESPIRATORY PATHOLOGY IN CHILDREN AND APPLICATION THEREOF | 2020 |
|
RU2759652C1 |
METHOD OF PREDICTION OF MITOCHONDRIAL MALADIES IN INFANTS WITH UNDIFFERENTIATED FORMS OF NEUROPSYCHIC DELAY (VERSIONS) | 2008 |
|
RU2366959C1 |
ESTIMATE OF TISSUE ADAPTATION LEVEL TO ORGAN AND SYSTEM INCOMPETENCE BY EVALUATING COMPENSATORY PROLIFERATION OF MITOCHONDRIA IN RELATED TISSUE CELLS | 2007 |
|
RU2357247C1 |
METHOD FOR DETERMINATION OF GENETIC BASE OF COMMON TYPES OF HIGHER NERVOUS ACTIVITY (HNA) | 2009 |
|
RU2401071C1 |
PHARMACEUTICAL COMPOSITION CONTAINING ISOLATED MITOCHONDRIA AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF MYOSITIS | 2020 |
|
RU2810508C2 |
MEDICINAL AGENT FOR TREATING ALCOHOLISM-ASSOCIATED VISCERAL PATHOLOGY | 1989 |
|
RU2013091C1 |
METHOD FOR OPTIMAL PROFESSIONAL ORIENTATION IN CHILDREN AND TEENAGERS | 2003 |
|
RU2256436C2 |
Authors
Dates
2017-08-22—Published
2015-10-13—Filed